No of studies (ref) | Study Design | Limitations | Consistency | Generalizability to Population of Interest | Generalizability to intervention of interest | Relative Risk (95% CI) |
---|---|---|---|---|---|---|
Outcome: All-cause mortality: Quality of evidence: Low | ||||||
7 | RCTs | Sequence generation and allocation concealment was unclear in few of the included studies | I2= 50% | Yes (all studies were conducted in developing countries) | The median dose of supplementation was 10 mg/day and median duration of supplementation was for 6 months. | 0.91 (0.82-1.01) |
Outcome: Diarrhea specific mortality: Quality of evidence: Low | ||||||
4 | RCTs | Allocation concealment was unclear in two of the included studies | I2=0% | Yes (all studies were conducted in developing countries) | The median dose of supplementation was 10 mg/day and median duration of supplementation was for 6 months. | 0.82 (0.64-1.05) |
Outcome: Diarrhea specific morbidity: Quality of evidence: Moderate | ||||||
14 | RCTs | Sequence generation and allocation concealment was unclear in few of the included studies | I2=79% | Yes (all studies were conducted in developing countries) | The median dose of supplementation was 10 mg/day and median duration of supplementation was for 6 months. | 0.87 (0.81-0.94) |
Outcome: Pneumonia specific mortality: Quality of evidence: Low | ||||||
4 | RCTs | Allocation concealment was unclear in two of the included studies | I2= 39% | Yes (all studies were conducted in developing countries) | The median dose of supplementation was 10 mg/day and median duration of supplementation was for 6 months. | 0.85 (0.65-1.11) |
Outcome: Pneumonia specific morbidity: Quality of evidence: Moderate | ||||||
6 | RCTs | Sequence generation and allocation concealment was unclear in few of the included studies | I2=0% | Yes (all studies were conducted in developing countries) | The median dose of supplementation was 10 mg/day and median duration of supplementation was for 6 months. | 0.81 (0.73-0.90) |
Outcome: Malaria specific mortality: Quality of evidence: Low | ||||||
1 | RCT | None | NA | Study conducted in Zanzibar | Dose of supplementation was 10 mg/dl for children > 1 year and 5mg/day for children < 1 years. | 0.90 (0.77-1.06) |
Outcome: Malaria specific morbidity: Quality of evidence: Low | ||||||
4 | RCTs | Allocation concealment was unclear in two of the included studies | I2=0% | Yes (all studies were conducted in developing countries) | The median dose of supplementation was 10 mg/day and median duration of supplementation was for 6 months. | 0.92 (0.82-1.04) |